Find Ganciclovir manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

125RELATED EXCIPIENT COMPANIES

204EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as:
Molecular Formula
C9H13N5O4
Molecular Weight
255.23  g/mol
InChI Key
IRSCQMHQWWYFCW-UHFFFAOYSA-N

Ganciclovir
1 2D Structure

Ganciclovir

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2.1.2 InChI
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
2.1.3 InChI Key
IRSCQMHQWWYFCW-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=NC2=C(N1COC(CO)CO)NC(=NC2=O)N
2.1.5 Isomeric SMILES
C1=NC2=C(N1COC(CO)CO)NC(=NC2=O)N
2.2 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 255.23 g/mol
Molecular Formula C9H13N5O4
XLogP3-1.7
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count5
Rotatable Bond Count5
Exact Mass255.09675391 g/mol
Monoisotopic Mass255.09675391 g/mol
Topological Polar Surface Area135 A^2
Heavy Atom Count18
Formal Charge0
Complexity346
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 6  
Drug NameCytovene
PubMed HealthGanciclovir (Injection)
Drug ClassesAntiviral
Drug LabelGanciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV). CYTOVENE-IV is the brand name for ganciclovir sodium for injection.CYTOVENE-IV is available as sterile lyophilized powder in strength of 500 mg per vial for intraveno...
Active IngredientGanciclovir sodium
Dosage FormInjectable
RouteInjection
Strengtheq 500mg base/vial
Market StatusPrescription
CompanyRoche Palo

2 of 6  
Drug NameGanciclovir
PubMed HealthGanciclovir
Drug ClassesAntiviral
Drug LabelGanciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV).Ganciclovir is available as 250 mg and 500 mg capsules. Each capsule contains 250 mg or 500 mg ganciclovir, USP respectively, and inactive ingredients croscarmellose s...
Active IngredientGanciclovir sodium
Dosage FormInjectable
RouteInjection
Strengtheq 500mg base/vial
Market StatusPrescription
CompanyFresenius Kabi Usa; Luitpold

3 of 6  
Drug NameZirgan
PubMed HealthGanciclovir
Drug ClassesAntiviral
Drug LabelZIRGAN (ganciclovir ophthalmic gel) 0.15% contains a sterile, topical antiviral for ophthalmic use. The chemical name is 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (CAS number 82410-32-0). Ganciclovir is represented by the following structu...
Active IngredientGanciclovir
Dosage FormGel
RouteOphthalmic
Strength0.15%
Market StatusPrescription
CompanyBausch And Lomb

4 of 6  
Drug NameCytovene
PubMed HealthGanciclovir (Injection)
Drug ClassesAntiviral
Drug LabelGanciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV). CYTOVENE-IV is the brand name for ganciclovir sodium for injection.CYTOVENE-IV is available as sterile lyophilized powder in strength of 500 mg per vial for intraveno...
Active IngredientGanciclovir sodium
Dosage FormInjectable
RouteInjection
Strengtheq 500mg base/vial
Market StatusPrescription
CompanyRoche Palo

5 of 6  
Drug NameGanciclovir
PubMed HealthGanciclovir
Drug ClassesAntiviral
Drug LabelGanciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV).Ganciclovir is available as 250 mg and 500 mg capsules. Each capsule contains 250 mg or 500 mg ganciclovir, USP respectively, and inactive ingredients croscarmellose s...
Active IngredientGanciclovir sodium
Dosage FormInjectable
RouteInjection
Strengtheq 500mg base/vial
Market StatusPrescription
CompanyFresenius Kabi Usa; Luitpold

6 of 6  
Drug NameZirgan
PubMed HealthGanciclovir
Drug ClassesAntiviral
Drug LabelZIRGAN (ganciclovir ophthalmic gel) 0.15% contains a sterile, topical antiviral for ophthalmic use. The chemical name is 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (CAS number 82410-32-0). Ganciclovir is represented by the following structu...
Active IngredientGanciclovir
Dosage FormGel
RouteOphthalmic
Strength0.15%
Market StatusPrescription
CompanyBausch And Lomb

API SUPPLIERS

read-more
read-more

01

Unimark Remedies

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

USDMF CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF Others AUDIT
Company Banner

02

Shamrock Pharmachemi

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTogether we can improve the quality of life

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

03

Fareva

Luxembourg

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFareva: One stop for innovative drug development, precision manufacturing and high-quality APIs.

Flag Luxembourg
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
Company Banner

04

CHANGZHOU KONY PHARMACEUTICAL CO.,...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

CHANGZHOU KONY PHARMACEUTICAL CO.,...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Trifarma

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Trifarma

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

06

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

07

Charioteer

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Charioteer

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF Inactive-api CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

08

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

09

Shanghai Pharma Group

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Shanghai Pharma Group

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

10

Unipex

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Unipex

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more
  • Development Update

Details:

Stimotimagene Copolymer Plasmid is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sarcoma.


Lead Product(s): Stimotimagene Copolymer Plasmid,Ganciclovir

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Cell & Gene Therapy

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 13, 2022

blank

01

Gene Surgery LLC

Country
arrow
PEGS Boston Summit
Not Confirmed

Gene Surgery LLC

Country
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Stimotimagene Copolymer Plasmid,Ganciclovir

Therapeutic Area : Oncology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Stimotimagene Copolymer Plasmid is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sarcoma.

Product Name : Undisclosed

Product Type : Cell & Gene Therapy

Upfront Cash : Inapplicable

October 13, 2022

blank
  • Development Update

Details:

Gancyclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.


Lead Product(s): Ganciclovir,Foscarnet Sodium

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Biotest

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 12, 2022

blank

02

University Hospital, Lille

Country
arrow
PEGS Boston Summit
Not Confirmed

University Hospital, Lille

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Gancyclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 12, 2022

blank

Details:

Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.


Lead Product(s): Human Cytomegalovirus Immune Globulin,Ganciclovir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cytogam

Study Phase: Approved FDFProduct Type: Protein

Sponsor: Kamada

Deal Size: $145.0 million Upfront Cash: $95.0 million

Deal Type: Acquisition November 22, 2021

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.

Product Name : Cytogam

Product Type : Protein

Upfront Cash : $95.0 million

November 22, 2021

blank
  • Development Update

Details:

Cytomegalovirus Specific T Lymphocytes is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cytomegalovirus Infections.


Lead Product(s): Cytomegalovirus Specific T Lymphocytes,Foscarnet Sodium,Ganciclovir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Cell & Gene Therapy

Sponsor: Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 28, 2016

blank

04

Shanghai General Hospital

Country
arrow
PEGS Boston Summit
Not Confirmed

Shanghai General Hospital

Country
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Cytomegalovirus Specific T Lymphocytes,Foscarnet Sodium,Ganciclovir

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Cytomegalovirus Specific T Lymphocytes is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cytomegalovirus Infections.

Product Name : Undisclosed

Product Type : Cell & Gene Therapy

Upfront Cash : Inapplicable

December 28, 2016

blank
  • Development Update

Details:

Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratitis, Herpetic.


Lead Product(s): Ganciclovir,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Bausch & Lomb Incorporated

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 06, 2015

blank

05

Northwestern University

Country
arrow
PEGS Boston Summit
Not Confirmed

Northwestern University

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratitis, Herpetic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 06, 2015

blank

Details:

Rabbit Anti-Thymocyte Globulin is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Transplantation.


Lead Product(s): Rabbit Anti-Thymocyte Globulin,Everolimus,Tacrolimus,Mycophenolate Mofetil,Prednisone,Ganciclovir,Valganciclovir Hydrochloride

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Antibody, Unconjugated

Sponsor: Rho, Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 14, 2014

blank

06

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Rabbit Anti-Thymocyte Globulin is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Transplantation.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

July 14, 2014

blank
  • Development Update

Details:

Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis.


Lead Product(s): Ganciclovir,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 17, 2012

blank

07

Adapt Produtos Oftalmológicos

Country
arrow
PEGS Boston Summit
Not Confirmed

Adapt Produtos Oftalmológicos

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 17, 2012

blank
  • Development Update

Details:

Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Keratoconjunctivitis.


Lead Product(s): Ganciclovir,Inapplicable

Therapeutic Area: Ophthalmology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Bausch & Lomb Incorporated

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 15, 2012

blank

08

Lifelong Vision Foundation

Country
arrow
PEGS Boston Summit
Not Confirmed

Lifelong Vision Foundation

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Keratoconjunctivitis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 15, 2012

blank

Details:

Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Lung Injury.


Lead Product(s): Ganciclovir,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: National Heart, Lung, and Blood Institute | Genentech

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 15, 2011

blank

09

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Ganciclovir,Inapplicable

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : National Heart, Lung, and Blood Institute | Genentech

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Lung Injury.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 15, 2011

blank
  • Development Update

Details:

CMV-Specific T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.


Lead Product(s): CMV-Specific T Cell,Ganciclovir,Valganciclovir Hydrochloride,Foscarnet Sodium

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Cell & Gene Therapy

Sponsor: Leukaemia Lymphoma Research | NHS Blood and Transplant | University of Birmingham

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 14, 2010

blank

10

Cell Medica

Country
arrow
PEGS Boston Summit
Not Confirmed

Cell Medica

Country
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : CMV-Specific T Cell,Ganciclovir,Valganciclovir Hydrochloride,Foscarnet Sodium

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Leukaemia Lymphoma Research | NHS Blood and Transplant | University of Birmingham

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : CMV-Specific T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.

Product Name : Undisclosed

Product Type : Cell & Gene Therapy

Upfront Cash : Inapplicable

October 14, 2010

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Granulation

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Parenteral

read-more
read-more

Taste Masking

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Solubilizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Lubricants & Glidants

read-more
read-more

Empty Capsules

read-more
read-more

Coating Systems & Additives

read-more
read-more

Controlled & Modified Release

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Emulsifying Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for / Ganciclovir API manufacturers, exporters & distributors?

Ganciclovir manufacturers, exporters & distributors 1

16

PharmaCompass offers a list of Ganciclovir API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ganciclovir manufacturer or Ganciclovir supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ganciclovir manufacturer or Ganciclovir supplier.

API | Excipient name

Ganciclovir

Ganciclovir & D5-dgA immunotoxin Manufacturers

A Ganciclovir & D5-dgA immunotoxin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ganciclovir & D5-dgA immunotoxin, including repackagers and relabelers. The FDA regulates Ganciclovir & D5-dgA immunotoxin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ganciclovir & D5-dgA immunotoxin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Ganciclovir & D5-dgA immunotoxin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Ganciclovir & D5-dgA immunotoxin Suppliers

A Ganciclovir & D5-dgA immunotoxin supplier is an individual or a company that provides Ganciclovir & D5-dgA immunotoxin active pharmaceutical ingredient (API) or Ganciclovir & D5-dgA immunotoxin finished formulations upon request. The Ganciclovir & D5-dgA immunotoxin suppliers may include Ganciclovir & D5-dgA immunotoxin API manufacturers, exporters, distributors and traders.

click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Ganciclovir & D5-dgA immunotoxin USDMF

A Ganciclovir & D5-dgA immunotoxin DMF (Drug Master File) is a document detailing the whole manufacturing process of Ganciclovir & D5-dgA immunotoxin active pharmaceutical ingredient (API) in detail. Different forms of Ganciclovir & D5-dgA immunotoxin DMFs exist exist since differing nations have different regulations, such as Ganciclovir & D5-dgA immunotoxin USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Ganciclovir & D5-dgA immunotoxin DMF submitted to regulatory agencies in the US is known as a USDMF. Ganciclovir & D5-dgA immunotoxin USDMF includes data on Ganciclovir & D5-dgA immunotoxin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ganciclovir & D5-dgA immunotoxin USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with USDMF on PharmaCompass.

Ganciclovir & D5-dgA immunotoxin JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Ganciclovir & D5-dgA immunotoxin Drug Master File in Japan (Ganciclovir & D5-dgA immunotoxin JDMF) empowers Ganciclovir & D5-dgA immunotoxin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Ganciclovir & D5-dgA immunotoxin JDMF during the approval evaluation for pharmaceutical products. At the time of Ganciclovir & D5-dgA immunotoxin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with JDMF on PharmaCompass.

Ganciclovir & D5-dgA immunotoxin CEP

A Ganciclovir & D5-dgA immunotoxin CEP of the European Pharmacopoeia monograph is often referred to as a Ganciclovir & D5-dgA immunotoxin Certificate of Suitability (COS). The purpose of a Ganciclovir & D5-dgA immunotoxin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ganciclovir & D5-dgA immunotoxin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ganciclovir & D5-dgA immunotoxin to their clients by showing that a Ganciclovir & D5-dgA immunotoxin CEP has been issued for it. The manufacturer submits a Ganciclovir & D5-dgA immunotoxin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ganciclovir & D5-dgA immunotoxin CEP holder for the record. Additionally, the data presented in the Ganciclovir & D5-dgA immunotoxin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ganciclovir & D5-dgA immunotoxin DMF.

A Ganciclovir & D5-dgA immunotoxin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ganciclovir & D5-dgA immunotoxin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with CEP (COS) on PharmaCompass.

Ganciclovir & D5-dgA immunotoxin WC

A Ganciclovir & D5-dgA immunotoxin written confirmation (Ganciclovir & D5-dgA immunotoxin WC) is an official document issued by a regulatory agency to a Ganciclovir & D5-dgA immunotoxin manufacturer, verifying that the manufacturing facility of a Ganciclovir & D5-dgA immunotoxin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ganciclovir & D5-dgA immunotoxin APIs or Ganciclovir & D5-dgA immunotoxin finished pharmaceutical products to another nation, regulatory agencies frequently require a Ganciclovir & D5-dgA immunotoxin WC (written confirmation) as part of the regulatory process.

click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with Written Confirmation (WC) on PharmaCompass.

Ganciclovir & D5-dgA immunotoxin NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ganciclovir & D5-dgA immunotoxin as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Ganciclovir & D5-dgA immunotoxin API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Ganciclovir & D5-dgA immunotoxin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Ganciclovir & D5-dgA immunotoxin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ganciclovir & D5-dgA immunotoxin NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with NDC on PharmaCompass.

Ganciclovir & D5-dgA immunotoxin GMP

Ganciclovir & D5-dgA immunotoxin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Ganciclovir & D5-dgA immunotoxin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ganciclovir & D5-dgA immunotoxin GMP manufacturer or Ganciclovir & D5-dgA immunotoxin GMP API supplier for your needs.

Ganciclovir & D5-dgA immunotoxin CoA

A Ganciclovir & D5-dgA immunotoxin CoA (Certificate of Analysis) is a formal document that attests to Ganciclovir & D5-dgA immunotoxin's compliance with Ganciclovir & D5-dgA immunotoxin specifications and serves as a tool for batch-level quality control.

Ganciclovir & D5-dgA immunotoxin CoA mostly includes findings from lab analyses of a specific batch. For each Ganciclovir & D5-dgA immunotoxin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Ganciclovir & D5-dgA immunotoxin may be tested according to a variety of international standards, such as European Pharmacopoeia (Ganciclovir & D5-dgA immunotoxin EP), Ganciclovir & D5-dgA immunotoxin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ganciclovir & D5-dgA immunotoxin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty